最新ニュース HCA Healthcare (NYSE:HCA) 株価情報

HCA Healthcare

HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2024, the firm owned and operated 190 hospitals, 124 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.

HCA Healthcare Inc

HOLDING CO ADMIE IPTO by Holding Co Admie Ipto SA

Holding Co ADMIE (IPTO) SA

Huachen AI Parking Management Technology Holding Co., Ltd. - Ordinary Shares

Huachen AI Parking Management Technology Holding Co Ltd

HALO COLLECTIVE INC by HALO COLLECTIVE INC.

Halo Collective Inc

Health Catalyst Inc

WIIM

HCA Healthcare shares are trading lower following Q1 earnings.

Wall Street's three-day rally came to a pause on Friday, with major indices hovering near the flatline by midday in New York as caution returned amid mixed signals on <a href="https://www.benzinga.com/news/global/25/04/45004954/china-reportedly-begins-exempting-key-us-imports-from-tariffs-including-pharma-and-aerospace-parts">U.S.-China trade relations.</a>
President Donald Trump claimed to have held a phone call with President Xi Jinping, yet Chinese officials denied that any talks had taken place.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) extended its rally into a fourth consecutive session, notching its best weekly performance of the year with a 16% gain. On Thursday afternoon, Transportation Secretary Sean Duffy introduced a new regulatory framework for self-driving vehicles, saying it aimed to reduce bureaucratic hurdles and advance toward a unified national standard.
T-Mobile US Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NYSE">TMUS</a>) was the biggest laggard of the day, falling 11%, on track for its worst single-day loss since March 2020. This came despite better-than-expected earnings, as its core wireless business posted slower growth than analysts had projected.
Among sectors, consumer discretionary led gains, buoyed by Tesla's 8% gain, while materials underperformed.
In fixed income, Treasury yields declined for a fourth straight session, underscoring how critical Trump's early-week reassurance — that he would not dismiss Fed Chair Jerome Powell — was for bond market sentiment.
The yield on the 10-year Treasury note dropped 4 basis points to 4.27%, on course for its lowest close since April 8.
In commodities, gold slid 2%, oil held steady at $62 per barrel, and natural gas rose 1% to $3 per million British thermal units, snapping a 10-session losing streak.
In crypto markets, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose 1.2% to $95,000.
<h2 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,250.90</td>
<td>+0.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,488.71</td>
<td>+0.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,908.60</td>
<td>-0.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,942.82</td>
<td colspan="2">-0.8%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) flattened at $546.92.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) eased 0.5% to $399.23.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;fell 0.2% to $468.61.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.7% to $192.79.</li>
<li>The&nbsp;Consumer Discretionary&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up 1.1%; the&nbsp;Materials Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) lagged, down 1.1%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
Stocks reacting to earnings report included:
<ul>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>): up 1.7%</li>
<li>T-Mobile US Inc.: down 10.9%</li>
<li>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>): up 2.4%</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>): down 7.2%</li>
<li>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>): down 3.2%</li>
<li>Aon plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>): down 11.0%</li>
<li>Republic Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>): down 0.2%</li>
<li>Digital Realty Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>): up 3.0%</li>
<li>HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>): down 5.2%</li>
<li>Charter Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>): up 10.3%</li>
<li>The Hartford Financial Services Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>): down 1.1%</li>
<li>Weyerhaeuser Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>): down 2.1%</li>
<li>Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>): up 1.1%</li>
<li>Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>): down 7.7%</li>
<li>LyondellBasell Industries N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>): up 0.0%</li>
<li>VeriSign Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>): up 9.1%</li>
<li>Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>): down 2.0%</li>
<li>Carrier Global Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>): down 0.5%</li>
<li>Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>): down 0.7%</li>
<li>Erie Indemnity Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>): down 11.8%</li>
<li>Principal Financial Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>): down 1.4%</li>
<li>Eastman Chemical Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>): down 6.0%</li>
<li>Healthpeak Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>): down 4.7%</li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45009066/goldman-sachs-upgrades-charles-schwab-to-buy-one-of-the-best-earnings-growth-outlooks-analyst-says">Goldman Sachs Upgrades Charles Schwab To Buy: &#8216;One Of The Best Earnings Growth Outlooks,&#8217; Analyst Says</a></li>
</ul>
Photo: Shutterstock

Equities

Government

Large Cap

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Econ #s

Economics

Tech

ETFs

$BTC

ABBV

CARR

CHTR

SPDR Dow Jones Industrial Average ETF Trust

ERIE

GILD

GOOGL

INTC

TMUS

TSLA

VRSN

Select Sector SPDR-Consumer Discretionary

Wall Street Rally Pauses, Tesla Heads For Strongest Week In 6 Months: What's Driving Markets Friday?

HCA Healthcare Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) reported on Friday that first-quarter 2025 revenues were $18.32 billion, up 6% year-over-year, slightly above the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $18.26 billion</a>.
The hospital chain reported adjusted EPS of $6.45, up from $5.36 a year ago, surpassing the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45005010/hca-healthcare-reports-first-quarter-2025-results" rel="noreferrer noopener">consensus of $5.76</a>.
In the first quarter of 2025, same-facility admissions increased by 2.6%, and same-facility equivalent admissions increased by 2.8%.
<ul>
<li>Same facility emergency room visits increased by 4%.</li>
<li>Same-facility inpatient surgeries increased by 0.2%, and same-facility outpatient surgeries declined by 2.1%.</li>
<li>Same facility revenue per equivalent admission increased 2.9% compared to the first quarter of 2024.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44995364/zoom-faces-international-growth-risks-amid-macroeconomic-and-tariff-headwinds-analyst" rel="noreferrer noopener">Zoom Faces International Growth Risks Amid Macroeconomic And Tariff Headwinds: Analyst</a>
HCA Healthcare CEO Sam Hazen said the company remains &#8220;encouraged&#8221; by the overall backdrop of growing demand for healthcare services.
Net income attributable to HCA Healthcare totaled $1.61 billion compared to $1.591 billion a year ago.
Adjusted EBITDA reached $3.73 billion in the first quarter of 2025, compared to $3.353 billion in the first quarter of 2024.
Guidance:&nbsp;HCA Healthcare reaffirms 2025 EPS of $24.05-$25.85 versus a consensus of $24.97 and a <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43192622/hca-healthcare-q4-earnings-beat-steet-estimates-despite-hurricane-impact-announces-10-billion-share-buyback-program" rel="noreferrer noopener">sales outlook of $72.8 billion—$75.8 billion</a> versus a consensus of $74.63 billion.
The company&#8217;s guidance incorporated its current expectations regarding volume growth coupled with an anticipated mostly stable operating environment, payer mix, the ongoing impacts of the two major 2024 hurricanes, the impact of current and future health care public policy developments, as well as general business or economic conditions, including inflation, and the impact of trade policies, including tariffs.
Price Action:&nbsp;HCA Healthcare stock is down 0.463% at $323.86&nbsp;at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44996394/chipotle-battles-slumping-sales-but-honey-chicken-boosts-hope-say-analysts" target="_blank" rel="noreferrer noopener">Chipotle Battles Slumping Sales, Analyst Pin Hope On Honey Chicken</a></li>
</ul>

Earnings

News

Guidance

Health Care

General

HCA Healthcare Shows Strong Pulse In Q1, Keeps 2025 Outlook Healthy

HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) affirms FY2025 GAAP EPS guidance from $24.05-$25.85 to $24.05-$25.85 vs $24.97 analyst estimate. Affirms FY2025 sales outlook from $72.80 billion-$75.80 billion to $72.80 billion-$75.80 billion vs $74.63 billion estimate.

HCA Healthcare Affirms FY2025 GAAP EPS Guidance of $24.05-$25.85 vs $24.97 Est; Affirms FY2025 Sales Guidance of $72.80B-$75.80B vs $74.63B Est

HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) reported quarterly earnings of $6.45 per share which beat the analyst consensus estimate of $5.76 by 11.98 percent. This is a 20.34 percent increase over earnings of $5.36 per share from the same period last year. The company reported quarterly sales of $18.32 billion which beat the analyst consensus estimate of $18.26 billion by 0.35 percent. This is a 5.66 percent increase over sales of $17.34 billion the same period last year.

Earnings Beats

HCA Healthcare Q1 Adj. EPS $6.45 Beats $5.76 Estimate, Sales $18.32B Beat $18.26B Estimate

U.S. stock futures traded mixed on Friday after three consecutive days of gains, with S&amp;P 500 futures edging higher amid <a href="https://benzinga.com/analyst-ratings/analyst-color/25/04/44988781/wall-street-rally-extends-into-third-day-whats-driving-markets-thursday">rising earnings optimism</a> and signs of easing U.S.-China trade tensions.
The first quarter earnings report of Google-parent Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) topped estimates, adding to investor confidence following weeks of uncertainty.
Investors will be keeping an eye on AbbVie Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>),&nbsp;HCA Healthcare Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), and&nbsp;Aon PLC&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>), among several other corporate earnings that are set to be released on Friday. 
U.S. 10-Year Treasury yields stood at 4.3% and 2-Year Treasury yields at 3.80%. According to the CME Group&#8217;s FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a> predictions, there is a 95.3% chance of the Federal Reserve keeping interest rates unchanged during its next meeting in May.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.13%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>+0.20%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>+0.22%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.48%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) dipped 0.19% and 0.37%, respectively, in Friday's premarket trading, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;17jsfbw&#x2A;_gcl_au&#x2A;MjA5Njc0MjY1My4xNzQwODM2NTUw&#x2A;_ga&#x2A;R1MxLjEuMTc0NDY0ODA3Mi4yLjAuMTc0NDY0ODA3NS4wLjAuMA..&#x2A;_ga_V7ZK73W7N0&#x2A;MTc0NTU3MTI2OS4xLjEuMTc0NTU3MTQ4My4wLjAuMA..">Benzinga Pro</a> data.
Cues From Last Session: 
The markets were buoyed by the strong performance of Alphabet and T-Mobile US Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>), but several others, such as Procter &amp; Gamble Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) and PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>), fell short of estimates.
Economic data was largely mixed on Thursday, with the Initial Jobless Claims report at 220,000, against a forecast of 222,000, while Existing Home Sales came in at 4.03 million, falling short of the median forecast at 4.13 million.
All S&amp;P 500 sectors advanced on Thursday, barring consumer staples, which declined 0.88% owing to the lackluster earnings of PepsiCo and Procter &amp; Gamble during the day.
As of Thursday, the Nasdaq 100 was down 13.5% from its previous high of 22,222.61 points, the S&amp;P 500 was down 10.8% from a high of 6147.43 points, and finally, the Dow Jones Industrial Average was down 11% from its high of 45,073.63.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>2.74%</td>
<td>17,166.04</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>2.03%</td>
<td>5,484.77</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>1.23%</td>
<td>40,093.40</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2.00%</td>
<td>1,957.59</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts: 
Market analyst, Ryan Detrick, highlighted the fact that the S&amp;P 500 has risen by at least 1.5% for three trading days in a row, saying that, &#8220;This isn&#8217;t stuff you see in bear market rallies or short covering rallies.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The S&amp;P 500 is up at least 1.5% for three days in a row. This isn&#39;t stuff you see in bear market rallies or short covering rallies. You see this before times of strong performance. Higher 10 out of 10 times a year later and up 21.6% on average. <a href="https://t.co/kfvfNKq6IK">pic.twitter.com/kfvfNKq6IK</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1915608371840921812?ref_src=twsrc%5Etfw">April 25, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
&#8220;You see this before times of strong performance,&#8221; he says, &#8220;higher 10 out of 10 times a year later and up 21.6% on average,&#8221; each time you see three consecutive daily gains of 1.5% or more in the S&amp;P 500.
Upcoming Economic Data:
Here&#8217;s what investors will be looking at on Friday,
<ul>
<li>The Consumer Sentiment (Final) report is set to be released at 10 AM Eastern Time on Friday.</li>
</ul>
Stocks In Focus:
<ul>
<li>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) is up 2.40% in pre-market trade as it is set to report its earnings this morning, with analysts expecting earnings of $2.40 per share, on $12.9 billion in revenue. </li>
<li>HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) is down 0.43% pre-market and is set to report its earnings before the bell, with analysts expecting $5.75 per share, on $18.3 billion in revenue. </li>
<li>Aon PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) is set to report its earnings prior to the opening bell and is up 1.08% pre-market. Analysts expect earnings of $6.03 per share, on $4.8 billion in revenue. </li>
<li>Colgate-Palmolive Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) is up 0.18% in pre-market trade in anticipation of its first quarter earnings prior to the opening bell. Analysts expect the FMCG giant to post $0.86 per share in earnings, on $4.8 billion in revenue. </li>
<li>Charter Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) is down 4.8% in pre-market trade and is set to report its first quarter results before markets open. Analysts expect $8.59 per share in earnings and $13.7 billion in revenue.</li>
</ul>
Commodities, Gold And Global Equity Markets
Crude oil futures are trading down 0.68% in the early New York session on Friday, at $62.63 per barrel.
The U.S. Dollar Index (DXY) is up 0.37%, trading at 99.74, while gold spot prices continue to witness a pullback, trading at 3,299.63, down 1.08%.
Asian markets edged higher on Friday, with the Nikkei 225, Kospi, and Shenzhen ending the day in the green, along with Australia&#8217;s ASX 200. India&#8217;s Nifty 50 and the Sensex are ending the week down.
Image Via shutterstock

Markets

Analyst Ratings

GOOG

US Stock Futures Mixed After Three-Day Winning Streak: Expert Dismisses Market Pessimism, Says 'This Isn't Stuff You See In Bear Market'

<h3>Companies Reporting Before The Bell</h3>
• Gentex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTX#NASDAQ">GNTX</a>) is projected to report quarterly earnings at $0.42 per share on revenue of $572.09 million. 
• Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) is estimated to report quarterly earnings at $2.76 per share on revenue of $811.53 million. 
• Phinia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHIN#NYSE">PHIN</a>) is estimated to report quarterly earnings at $1.00 per share on revenue of $814.11 million. 
• Virtus Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTS#NYSE">VRTS</a>) is estimated to report quarterly earnings at $5.41 per share on revenue of $201.41 million. 
• Stellar Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEL#NYSE">STEL</a>) is expected to report quarterly earnings at $0.44 per share on revenue of $105.66 million. 
• AutoNation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) is estimated to report quarterly earnings at $4.38 per share on revenue of $6.64 billion. 
• Sensient Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXT#NYSE">SXT</a>) is estimated to report quarterly earnings at $0.82 per share on revenue of $387.70 million. 
• Carter's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRI#NYSE">CRI</a>) is projected to report quarterly earnings at $0.52 per share on revenue of $623.41 million. 
• Flagstar Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLG#NYSE">FLG</a>) is expected to report quarterly loss at $0.28 per share on revenue of $509.58 million. 
• Portland Gen Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) is estimated to report quarterly earnings at $0.99 per share on revenue of $970.49 million. 
• AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) is likely to report quarterly earnings at $2.38 per share on revenue of $12.92 billion. 
• HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) is expected to report quarterly earnings at $5.76 per share on revenue of $18.26 billion. 
• Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) is projected to report quarterly earnings at $8.69 per share on revenue of $13.68 billion. 
• Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) is projected to report quarterly earnings at $0.74 per share on revenue of $8.60 billion. 
• Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) is expected to report quarterly loss at $0.72 per share on revenue of $31.33 billion. 
• Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) is projected to report quarterly earnings at $0.86 per share on revenue of $4.86 billion. 
• LyondellBasell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) is expected to report quarterly earnings at $0.43 per share on revenue of $7.46 billion. 
• Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) is expected to report quarterly earnings at $6.02 per share on revenue of $4.86 billion. 
• Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) is expected to report quarterly earnings at $2.54 per share on revenue of $43.36 billion. 
• Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) is expected to report earnings for its fourth quarter. 
• Lakeland Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKFN#NASDAQ">LKFN</a>) is expected to report quarterly earnings at $0.89 per share on revenue of $63.71 million. 
• GrafTech International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAF#NYSE">EAF</a>) is likely to report quarterly loss at $0.13 per share on revenue of $122.33 million. 
• Avantor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) is projected to report quarterly earnings at $0.23 per share on revenue of $1.61 billion. 
• Oxford Square Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXSQ#NASDAQ">OXSQ</a>) is expected to report quarterly earnings at $0.08 per share on revenue of $9.90 million. 
• Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) is expected to report quarterly earnings at $0.36 per share on revenue of $654.15 million. 
• Preferred Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFBC#NASDAQ">PFBC</a>) is estimated to report quarterly earnings at $2.33 per share on revenue of $70.51 million. 
• Rithm Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RITM#NYSE">RITM</a>) is likely to report quarterly earnings at $0.47 per share on revenue of $1.27 billion. 
• Trinet Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNET#NYSE">TNET</a>) is projected to report quarterly earnings at $1.61 per share on revenue of $319.36 million. 
<h3>Companies Reporting After The Bell</h3>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADXN

AVTR

GNTX

LKFN

OXSQ

PFBC

PHIN

RITM

SAIA

STEL

TNET

VRTS

Earnings Scheduled For April 25, 2025

U.S. stock futures are up Thursday night following <a href="https://benzinga.com/analyst-ratings/analyst-color/25/04/44988781/wall-street-rally-extends-into-third-day-whats-driving-markets-thursday">three back-to-back days</a> in the green during the regular session, amid growing earnings optimism and easing trade tensions.
The S&amp;P 500 Futures are up 0.37%, at 5,531, followed by Nasdaq Futures at 19,416, up 0.49%, and finally Dow Futures trading flat at 40,248, down 0.03%. All three major averages are up for the week, with one day left to go. 
See More: <a href="https://www.benzinga.com/25/04/44999320/japans-counterpunch-to-trump-tariffs-emergency-measures-deployed-as-us-trade-talks-loom">Japan&#8217;s Counterpunch To Trump Tariffs: Emergency Measures Deployed As US Trade Talks Loom</a>
Japan&#8217;s Nikkei 225 benchmark index opened higher on Friday morning, marking its third-straight session of gains. It is up 1.57%, or 528 points, at the time of writing this, taking cues from Wall Street. Tech stocks are leading the rally, while entertainment, retail, and real estate witness a pullback. Japan&#8217;s government has <a href="https://www.benzinga.com/25/04/44999320/japans-counterpunch-to-trump-tariffs-emergency-measures-deployed-as-us-trade-talks-loom">announced a number of emergency countermeasures</a> to combat the adverse effects of tariffs imposed by the United States.
The U.S. Dollar Index (DXY) is up 0.17%, trading at 99.55, and is now up 0.21% for the week, after hitting a three-year low of 97.96 on Monday. 
Investors will be waiting for the Consumer Sentiment Report on Friday morning, while also closely watching the earnings of AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), and Aon PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>), among several others.
Photo Courtesy: Chokchai Poomichaiya on Shutterstock.com
Read More: <a href="https://benzinga.com/analyst-ratings/analyst-color/25/04/44988781/wall-street-rally-extends-into-third-day-whats-driving-markets-thursday">Wall Street Rally Extends Into Third Day: What&#8217;s Driving Markets Thursday?</a>

US Futures Gain Amid Back-To-Back Gains On Wall Street, Nikkei Opens In The Green, Dollar Edges Higher

HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) will release its quarterly earnings report on Friday, 2025-04-25. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate HCA Healthcare to report an earnings per share (EPS) of $5.79.
The market awaits HCA Healthcare's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
Last quarter the company beat EPS by $0.08, which was followed by a 0.0% drop in the share price the next day.
Here's a look at HCA Healthcare's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>6.14</td>
<td>4.97</td>
<td>4.88</td>
<td>5.01</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>6.22</td>
<td>4.90</td>
<td>5.50</td>
<td>5.36</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-9.0%</td>
<td>1.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745503235_0.png" alt="eps graph" />
<h3>Tracking HCA Healthcare's Stock Performance</h3>
Shares of HCA Healthcare were trading at $335.98 as of April 23. Over the last 52-week period, shares are up 10.45%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/HCA/earnings">To track all earnings releases for HCA Healthcare visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For HCA Healthcare

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Barclays analyst Dan Levy downgraded the rating for General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) from Overweight to Equal-Weight and lowered the price target from $70 to $40. General Motors shares closed at $45.14 on Monday. <a href="https://www.benzinga.com/quote/GM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Michael Ha downgraded HCA Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) from Outperform to Neutral and cut the price target from $396 to $336. HCA Healthcare shares closed at $340.62 on Monday. <a href="https://www.benzinga.com/quote/HCA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Amy Li downgraded the rating for Ironwood Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) from Buy to Hold and cut the price target from $8 to $0.7. Ironwood Pharmaceuticals shares closed at $0.6479 on Monday. <a href="https://www.benzinga.com/quote/IRWD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jones Trading analyst Catherine Novack downgraded the rating for Rallybio Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) from Buy to Hold. Rallybio shares closed at $0.2702 on Monday. <a href="https://www.benzinga.com/quote/RLYB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Dan Levy downgraded Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) from Overweight to Equal-Weight and cut the price target from $22 to $14. Mobileye Global shares closed at $12.94 on Monday.  <a href="https://www.benzinga.com/quote/MBLY/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying GM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15082139/image-112-1024x587.png" alt="" class="wp-image-872090" style="width:609px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15082139/image-112-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15082139/image-112-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15082139/image-112-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15082139/image-112.png 1085w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44806916/citigroup-bank-of-america-and-3-stocks-to-watch-heading-into-tuesday">Citigroup, Bank Of America And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Pre-Market Outlook

Trading Ideas

IRWD

MBLY

RLYB

This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Baird analyst Michael Ha downgrades HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) from Outperform to Neutral and lowers the price target from $396 to $336.

Price Target

Baird Downgrades HCA Healthcare to Neutral, Lowers Price Target to $336

Guggenheim analyst Jason Cassorla initiates coverage on HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Neutral rating.

Initiation

Guggenheim Initiates Coverage On HCA Healthcare with Neutral Rating

In the current market session, HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) stock price is at $337.19, after a 0.03% decrease. However, over the past month, the company's stock went up by 6.70%, and in the past year, by 3.74%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1743105619_0.png" alt="Past Year Chart" />

<h3>HCA Healthcare P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 18.19 in the Health Care Providers &amp; Services industry, HCA Healthcare Inc. has a lower P/E ratio of 15.33. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1743105619_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Price Over Earnings Overview: HCA Healthcare

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$24.00</td>
<td>$50.5K</td>
<td>2.0K</td>
<td>2.0K</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$30.00</td>
<td>$60.2K</td>
<td>2.8K</td>
<td>1.6K</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/28/25</td>
<td>$320.00</td>
<td>$473.7K</td>
<td>609</td>
<td>602</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$320.00</td>
<td>$312.3K</td>
<td>43</td>
<td>502</td>
</tr>
<tr>
<td>AKRO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$27.50</td>
<td>$35.0K</td>
<td>2.4K</td>
<td>469</td>
</tr>
<tr>
<td>GERN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$1.00</td>
<td>$33.7K</td>
<td>413</td>
<td>397</td>
</tr>
<tr>
<td>EWTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$30.00</td>
<td>$32.2K</td>
<td>5.4K</td>
<td>332</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$230.00</td>
<td>$53.6K</td>
<td>6.9K</td>
<td>295</td>
</tr>
<tr>
<td>CAH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$130.00</td>
<td>$44.2K</td>
<td>2.6K</td>
<td>188</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$57.50</td>
<td>$64.9K</td>
<td>9.5K</td>
<td>167</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option sweep with neutral sentiment. It expires in 56 day(s) on May 16, 2025. Parties traded 200 contract(s) at a $24.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $50.5K, with a price of $253.0 per contract. There were 2012 open contracts at this strike prior to today, and today 2073 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a put option trade that happens to be bearish, is expiring today. Parties traded 300 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $60.2K, with a price of $201.0 per contract. There were 2865 open contracts at this strike prior to today, and today 1625 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bullish sentiment. It expires in 7 day(s) on March 28, 2025. Parties traded 600 contract(s) at a $320.00 strike. This particular put needed to be split into 57 different trades to become filled. The total cost received by the writing party (or parties) was $473.7K, with a price of $779.0 per contract. There were 609 open contracts at this strike prior to today, and today 602 contract(s) were bought and sold. 
• Regarding HCA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), we observe a put option sweep with bearish sentiment. It expires in 27 day(s) on April 17, 2025. Parties traded 474 contract(s) at a $320.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $312.3K, with a price of $660.0 per contract. There were 43 open contracts at this strike prior to today, and today 502 contract(s) were bought and sold. 
• For AKRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>), we notice a call option trade that happens to be bearish, is expiring today. Parties traded 20 contract(s) at a $27.50 strike. The total cost received by the writing party (or parties) was $35.0K, with a price of $1750.0 per contract. There were 2499 open contracts at this strike prior to today, and today 469 contract(s) were bought and sold. 
• Regarding GERN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>), we observe a call option trade with bearish sentiment. It expires in 210 day(s) on October 17, 2025. Parties traded 397 contract(s) at a $1.00 strike. The total cost received by the writing party (or parties) was $33.7K, with a price of $85.0 per contract. There were 413 open contracts at this strike prior to today, and today 397 contract(s) were bought and sold. 
• Regarding EWTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>), we observe a call option sweep with bullish sentiment. It expires in 27 day(s) on April 17, 2025. Parties traded 104 contract(s) at a $30.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $32.2K, with a price of $310.0 per contract. There were 5479 open contracts at this strike prior to today, and today 332 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option sweep that happens to be bearish, expiring in 91 day(s) on June 20, 2025. This event was a transfer of 198 contract(s) at a $230.00 strike. This particular call needed to be split into 35 different trades to become filled. The total cost received by the writing party (or parties) was $53.6K, with a price of $271.0 per contract. There were 6965 open contracts at this strike prior to today, and today 295 contract(s) were bought and sold. 
• For CAH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>), we notice a call option sweep that happens to be bullish, is expiring today. Parties traded 137 contract(s) at a $130.00 strike. This particular call needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $44.2K, with a price of $325.0 per contract. There were 2600 open contracts at this strike prior to today, and today 188 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a call option sweep with bearish sentiment. It expires in 91 day(s) on June 20, 2025. Parties traded 116 contract(s) at a $57.50 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $64.9K, with a price of $560.0 per contract. There were 9548 open contracts at this strike prior to today, and today 167 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AKRO

AMGN

EWTX

GERN

VKTX

10 Health Care Stocks Whale Activity In Today's Session

ENSG

UHAL

Shares of hospital an healthcare stocks are trading lower amid concerns over Medicaid an Medicare cuts. Additionally, President Trump recently signed an executive order on healthcare price transparency.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Shares of healthcare stocks are trading lower after President Trump signed an executive order on healthcare price transparency.

HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) has outperformed the market over the past 10 years by 5.72% on an annualized basis producing an average annual return of 17.15%. Currently, HCA Healthcare has a market capitalization of $84.87 billion. 
Buying $100 In HCA: If an investor had bought $100 of HCA stock 10 years ago, it would be worth $486.25 today based on a price of $335.07 for HCA at the time of writing.
<h3>HCA Healthcare's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738337414_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

A federal judge in the District of Columbia on Tuesday afternoon temporarily blocked an executive order given by President Donald Trump that imposed a freeze of all federal grants and loans, putting $3 trillion in funding in jeopardy and <a href="https://www.benzinga.com/25/01/43290381/trumps-federal-spending-freeze-puts-3-trillion-in-limbo-threatens-industries-like-clean-energy-defense-healthcare">entire industries on edge.&nbsp;</a>
The Details: According to a New York Times <a href="https://www.nytimes.com/2025/01/28/us/politics/trump-funding-freeze-blocked.html">report</a>, Judge Loren AliKhan blocked the order late Tuesday afternoon in response to a lawsuit filed by Democracy Forward. The lawsuit argued the directive violated the First Amendment and the Administrative Procedures Act governing the issuance of executive orders. 
Judge AliKhan said she will issue a more permanent decision on Feb. 3 
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/01/43106379/trump-reverses-bidens-ai-policies-on-day-1-what-it-means-for-tech-giants-nvidia-amd-alphabet">Trump Reverses Biden&#8217;s AI Policies On Day 1: What It Means For Tech Giants Nvidia, AMD, Alphabet&nbsp;</a>
Skye Perryman, Democracy Forward's president and chief executive, commented on the judge's decision in a statement.&nbsp;
"We are grateful for this administrative stay to allow our clients time to sort through the chaos created by the Trump administration's hasty and ill-advised actions," Perryman said, per the New York Times. 
Trump's directive, issued Monday by the Office of Management and Budget, required federal agencies to halt disbursements while programs were reviewed for alignment with Trump administration policies and was slated to go into effect on Tuesday at 5 p.m. ET.&nbsp;
But, early Tuesday, state Medicaid programs reported the federal reimbursement portals had been locked. State officials said funding for community health centers, food for families, housing assistance, preschools and disaster relief was in limbo.
According to the New York Times, the White House and OMB said on Tuesday afternoon the funding freeze did "not apply across-the-board" and affected programs on D.E.I. efforts and funding for organizations "that undermine the national interest."
Stocks To Watch: It remains unclear exactly which industries could be affected by Trump's order or if the judge will elect to block it permanently on Feb 3.&nbsp;
However, Medicaid funding had reportedly been stopped at least temporarily. HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) and Universal Health Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) stocks fell on Tuesday. 
Large defense contractors like RTX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) and Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) also face a growing degree of uncertainty regarding government funding and contracts.
Green industries including solar energy could also be on the chopping block for federal funding due to Trump administration policies. Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) dropped 12% Tuesday and Sunrun, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) fell 9.2% amid the uncertainty on future policy changes. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/43287988/microsoft-q2-preview">Microsoft Q2 Earnings Preview: Street &#8216;Too Optimistic&#8217; On Near-Term AI Returns?&nbsp;</a></li>
</ul>
Photo: Shutterstock

Politics

Legal

Movers

NOVA

Judge Blocks Trump's Order To Freeze Federal Grant Money

The White House has ordered a temporary freeze on all federal grants and loans, putting $3 trillion in funding under scrutiny and setting the stage for a legal and political showdown over the congressional power of the purse that could heavily impact a <a href="https://www.benzinga.com/markets">wide range of industries.</a>
The directive, issued Monday by the Office of Management and Budget and received by several media outlets, requires all federal agencies to halt disbursements while programs are reviewed for alignment with President Donald Trump's policy priorities.
This includes halting new awards, existing payment and funding for projects until reviewed.
The exact financial impact of the order remains uncertain. Budget experts cited <a href="https://www.washingtonpost.com/business/2025/01/28/trump-spending-freeze-upends-washington-triggering-legal-threats-delays/">by the Washington Post </a>estimate at least tens of billions of dollars are at stake, though the White House directive suggests the total could be significantly higher.
Of the almost $10 trillion spent by the federal government in fiscal 2024, more than $3 trillion was federal financial assistance, Matthew Vaeth, acting director at the OMB, said in the memorandum.
&#8220;Financial assistance should be dedicated to advancing Administration priorities,&#8221; Vaeth said, adding that &#8220;the use of Federal resources to advance Marxist equity, transgenderism, and green new deal social engineering policies is a waste of taxpayer dollars that does not improve the day-to-day lives of those we serve.&#8221;
The White House said that Social Security and Medicare remain untouched. The sweeping pause threatens funding for universities, nonprofits, contractors and private companies that depend on federal assistance.
&#8220;Nothing in this memo should be construed to impact Medicare or Social Security benefits,&#8221; the memo said. 
The immediate focus will be on how agencies handle exemptions. The OMB memo allows federal departments to request case-by-case approvals, which means some funding may still flow, but the process is likely to be slow and politically charged.
Federal agencies have until Feb. 10, 2025, to provide OMB with detailed reports outlining which programs, projects, and activities are affected by the funding pause.
<h3 class="wp-block-heading">Legal, Political Showdown Over Federal Funds </h3>
The move is triggering legal challenges from nonprofits and Democratic-led states.
Within hours of the announcement, lawsuits were filed in federal courts in New York, Illinois and Oregon, arguing that Trump does not have the authority to withhold congressionally approved spending.
Senate Minority Leader Chuck Schumer was among the first to push back, saying Congress-approved investments are legally mandated and asserting the president lacks the authority to override the Impoundment Control Act of 1974, which restricts unilateral executive control over federal funds.
Trump has long argued that the 1974 law is unconstitutional, stating that past presidents had far more discretion over spending before its passage.
<h3 class="wp-block-heading">Which Industries Could Face Trouble?</h3>
Some of the hardest-hit sectors could include clean energy, defense, health care and education, where federal dollars have played a crucial role in driving investment and growth in recent years.
Trump's OMB memo explicitly targeted climate initiatives and green energy programs. Shares of solar and renewable energy companies were among the hardest hit following the federal funding freeze.
The Invesco Solar ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAN#NYSE">TAN</a>) and the Invesco Wilderhill Clean Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBW#NYSE">PBW</a>) fell by 2% and 1.3%, respectively, on Tuesday. 
Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) dropped 12%, Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) fell 9.2% and SolarEdge Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) declined 5%. 
Defense contractors such as Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), RTX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) and Northrop Grumman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) may also see rising uncertainty. While military spending is unlikely to be cut outright, several defense contractors rely on federal grants for research and development. 
The impact on health care remains unclear. While Medicare is shielded, Medicaid funding — which supports hospitals, managed care providers and pharmaceutical companies — could be at risk.
HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) and Universal Health Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) fell by 1% and 1.4%, respectively, while Tenet Healthcare Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) showed resilience Tuesday. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43281252/fed-set-to-signal-no-rush-to-cut-rates-as-wall-street-awaits-policy-clarity">Fed Set To Signal No Rush To Cut Rates As Wall Street Awaits Policy Clarity</a></li>
</ul>
Photo via Shutterstock.

Sector ETFs

PowerShares Exchange Traded Fund Trust WilderHill Clean Energy Portfolio

SEDG

Trump's Federal Spending Freeze Puts $3 Trillion In Limbo, Threatens Industries Like Clean Energy, Defense, Health Care

RBC Capital analyst Ben Hendrix maintains HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Outperform and lowers the price target from $405 to $384.

RBC Capital Maintains Outperform on HCA Healthcare, Lowers Price Target to $384

Press Releases

HCA Announces Proposed Public Offering of Senior Notes

HCA Healthcare, Inc. to Present at March Healthcare Conferences

HCA Healthcare Recognized as One of the 2025 World's Most Ethical Companies by Ethisphere for the 15th Time

100 HCA Healthcare Hospitals Earn Healthgrades Patient Safety Excellence Award

HCA Healthcare Announces $1.84 Million HCA Healthcare Foundation Grant to United Way

HCA Healthcare Names Monica Cintado as Senior Vice President of Development

HCA Healthcare, Inc. 1st Quarter 2025 Earnings Conference Call

HCA Healthcare Named One of the World's Most Admired Companies by Fortune

Two Large Clinical Trials Find a Highly Effective Method to Select Appropriate Antibiotics for Patients Hospitalized With Abdominal or Skin and Soft Tissue Infection

Comments

HCA Healthcare

ニュース

最新ニュース HCA Healthcare (NYSE:HCA) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル